Scope International

Scope International

Hamburg, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Scope International is a well-established, privately-held German CRO with a 25-year track record, operating 11 offices across Europe and a global partner network. It offers end-to-end clinical development services, emphasizing flexibility, cost efficiency, and rapid timelines, which it contrasts favorably against larger, more rigid CROs. The company has developed its own proprietary technology platform to enhance service delivery and maintains strong therapeutic expertise across areas like pain, neurology, infectious diseases, and ATMPs. Its business model is purely service-based, generating revenue from pharmaceutical and biotech clients.

PainWomen's HealthRespiratoryNeurology & NeuropsychiatryInfectious DiseasesATMP

Technology Platform

Proprietary, modular platform including AI, CTMS, eTMF, EDC/ePRO/RTMS, Automated Safety Reporting, and eConsent capabilities. Built for flexibility and seamless integration.

Opportunities

Growing demand for flexible, service-oriented CROs from small to mid-sized biopharma companies.
Increased adoption of decentralized trial models and advanced technology in clinical research creates a market for its proprietary platform.
Expansion through its European office network and global partnerships.

Risk Factors

Intense competition from larger, resource-rich global CROs and other niche players.
Dependency on the health of the biopharma R&D sector and client outsourcing budgets.
Operational risks related to clinical trial execution, including recruitment and regulatory challenges.

Competitive Landscape

Competes against large, global full-service CROs (like IQVIA, PPD, ICON) and other regional European CROs. Differentiates through its emphasis on flexibility, responsiveness, and a client-service culture, positioning itself as an agile alternative to larger, sometimes rigid, competitors.